A Phase 2, Open-Label, Multicenter Study Investigating Efficacy and Safety of RP3 Oncolytic Immunotherapy Combined with Other Therapies in Patients with Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined